Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
| Condition | Intervention | Phase |
|---|---|---|
|
Bipolar Affective Disorder |
Drug: Mood stabilizer treatment |
Phase 4 |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) |
- Time to relapse [ Time Frame: every 2 months for 2 years ] [ Designated as safety issue: No ]
Relapse definition:
- meets criteria for mania and is considered "markedly ill" or worse; or
- meets criteria for major depression with 4 week duration;
- meets criteria for a mixed episode and is considered "markedly ill" or worse.
Biospecimen Retention: Samples With DNA
DNA from patients with bipolar disorder
| Estimated Enrollment: | 880 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | January 2016 |
| Estimated Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
lithium
All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
|
Drug: Mood stabilizer treatment
lithium or valproate
Other Names:
|
|
valproate
Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
|
Drug: Mood stabilizer treatment
lithium or valproate
Other Names:
|
Detailed Description:
All subjects meeting study inclusion criteria will be started on lithium. Those that fail lithium will be crossed over to valproate (VPA). Those that also fail VPA will be again crossed-over to a standardized treatment as usual (TAU) arm. Subjects who are eligible for the study must be at least 18 years of age and have been diagnosed or are thought to have bipolar I disorder with at least one episode of mood instability in the last 12 months. They must also be eligible to take lithium and, if female and of child bearing age, agree to use adequate birth control methods and to inform their doctor of their plans to become pregnant.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inpatient and outpatients with bipolar affective disorder
Inclusion Criteria:
- Any phase of bipolar I disorder including, depressive, manic, hypomanic, mixed, or baseline/euthymic/not symptomatic;
- Lithium naïve patients and inadequately past lithium treated patients will be required to have had at least one affective episode in the last 12 months meeting DSM-IV criteria. Current lithium treated patients (CLTPs) will be stable on lithium monotherapy and will be exempted from this criterion if they have had no mood episodes meeting DSM-IV criteria in the last 6 months;
- Both outpatients and inpatients will be permitted to enroll into this study;
- Able to give informed consent, in the judgment of the investigator;
- Age greater than or equal to 18 years;
- Women of child bearing potential agree to inform their doctor at the earliest possible time of their plans to conceive, and to use adequate contraception (e.g. oral contraceptives, intrauterine device, barrier methods, or total abstinence from intercourse), and to understand the risks of lithium to the fetus and infant. Depo Provera is acceptable if it is started 3 months prior to enrollment.
Exclusion Criteria:
- Unwilling or unable to comply with study requirements;
- Renal impairment (serum creatinine >1.5 mg/dL);
- Thyroid stimulating hormone (TSH) over >20% above the upper normal limit (participants maintained on thyroid medication must be euthyroid for at least 3 months before Visit 1;
- Other contraindication to lithium;
- Currently in crisis such that inpatient hospitalization or other crisis management should take priority;
- Subjects with alcohol/drug dependence who meet criteria for physical dependence requiring acute detoxification;
- Pregnant or breastfeeding;
- Women of child-bearing potential who aren't able to agree to the requirements specified above;
- Those who have participated in a clinical trial of an investigational drug within the past 1 month;
- Inability to agree to comply with the visit schedule or study procedures;
- History of lithium toxicity, not due to mismanagement or overdose that required treatment;
- Current unstable medical condition.
Contacts and Locations| Contact: Anna DeModena | 858-642-3590 | ademodena@ucsd.edu |
| Contact: Susan G Leckband, R.Ph. | 858-552-8585 ext 5337 | susan.leckband@va.gov |
| United States, California | |
| University of California San Diego | Recruiting |
| San Diego, California, United States, 92037 | |
| Contact: Anna DeModena 858-642-3590 ademodena@ucsd.edu | |
| Principal Investigator: John R. Kelsoe, MD | |
| United States, Illinois | |
| University of Chicago | Recruiting |
| Chicago, Illinois, United States, 60637 | |
| Contact: Ben Romanos 773-834-5128 bromanos@yoda.bsd.uchicago.edu | |
| Principal Investigator: Elliot Gershon, MD | |
| United States, Indiana | |
| Indiana University | Recruiting |
| Indianapolis, Indiana, United States, 46202 | |
| Contact: Carrie Fisher, RN 317-274-8844 cfisher2@iupui.edu | |
| Principal Investigator: John Nurnberger, MD | |
| United States, Iowa | |
| University of Iowa | Recruiting |
| Iowa City, Iowa, United States, 52242 | |
| Contact: Bruce H Tarwater, MSW, LISW 319-353-5684 bruce-tarwater@uiowa.edu | |
| Principal Investigator: William Coryell, MD | |
| United States, Maryland | |
| Johns Hopkins Hospital | Recruiting |
| Baltimore, Maryland, United States, 21287 | |
| Contact: Emma K Stokes, MHS 410-550-1652 estokes9@jhmi.edu | |
| Principal Investigator: Peter Zandi, PhD | |
| United States, Michigan | |
| University of Michigan | Recruiting |
| Ann Arbor, Michigan, United States, 48109-2700 | |
| Contact: Gloria Harrington 877-864-3637 BPResearch@umich.edu | |
| Principal Investigator: Melvin McInnis, MD | |
| United States, Ohio | |
| University Hospitals Case Medical Center | Recruiting |
| Cleveland, Ohio, United States, 44106 | |
| Contact: Carla Conroy 216-844-2871 Carla.Conroy@uhhospitals.org | |
| Principal Investigator: Joe Calabrese, MD | |
| United States, Pennsylvania | |
| University of Pennsylvania | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104-3309 | |
| Contact: Zachary Guy-Frank 215-746-6414 guyfrank@mail.med.upenn.edu | |
| Principal Investigator: Wade Berrettini, MD | |
| Canada, Nova Scotia | |
| Dalhousie University | Recruiting |
| Halifax, Nova Scotia, Canada, B3H 2E2 | |
| Contact: Julie Garnham, RN BN (902) 473-7144 jgarnham@dal.ca | |
| Contact: Claire Slaney (902) 473-5884 Claire.Slaney@cdha.nshealth.ca | |
| Principal Investigator: Martin Alda, MD | |
| Norway | |
| University of Bergen | Recruiting |
| Bergen, Norway, 5020 | |
| Contact: Petter Jakobsen (+47) 55 95 84 67 , petter.jakobsen@helse-bergen.no | |
| Principal Investigator: Ketil J Oedegaard, MD, PhD | |
| Principal Investigator: | John R Kelsoe, M.D. | University of California, San Diego |
More Information
Additional Information:
No publications provided
| Responsible Party: | John R. Kelsoe, MD, University of California, San Diego |
| ClinicalTrials.gov Identifier: | NCT01272531 History of Changes |
| Other Study ID Numbers: | NIH 1 U01 MH92758-01 |
| Study First Received: | January 6, 2011 |
| Last Updated: | April 9, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of California, San Diego:
|
pharmacogenetics bipolar disorders affective disorders mood disorders pharmacologic actions psychotropic drugs antimanic agents antidepressant agents |
lithium lithium carbonate Lithobid Eskalith divalproex divalproex sodium Depakote valproate |
Additional relevant MeSH terms:
|
Anticonvulsants Bipolar Disorder Mood Disorders Affective Disorders, Psychotic Mental Disorders Antidepressive Agents Lithium Carbonate Valproic Acid Lithium Psychotropic Drugs Central Nervous System Agents |
Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action GABA Agents Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Antipsychotic Agents |
ClinicalTrials.gov processed this record on May 16, 2013